Anthropic Launches Claude Science to Court Pharma Ahead of IPO
Katie Adams / medcitynews - Anthropic unveiled Claude Science, an AI workbench designed to run — not just assist with — pharma research. The company is seeking to build out its customer base in the pharma sector as it deepens its healthcare push ahead of a widely anticipated IPO.The…
AI Summary: Anthropic has rolled out Claude Science to court pharmaceutical partners and stake a claim in drug discovery, signaling a pivot from conversational AI toward biology and chemistry workflows. The move accelerates competition in AI‑driven target ID and molecule design, promising speed and scale — and giving traditional drug hunters a new set of algorithms to either fear or befriend.
Related Stories
Sanofi ousts Paul Hudson as Belén Garijo named incoming CEO / 4 months
AstraZeneca Secures Pan‑KRAS Inhibitor Deal with Jacobio Pharma / 6 months
Mass spectrometry platform could cut drug discovery to hours / 13 days
First-in-human trial primes immune system to accept donor livers / 2 months
Experimental therapy significantly reduces Parkinson’s toxic protein in early trial / 2 months
Keratin 16 restrains skin inflammation and may guide treatments / 2 months
Engineered CAR‑T cells secreting VEGF‑neutralizing scFvs boost solid‑tumor activity / 3 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Digital Health, Drug Pricing, Pancreatic Cancer, Long COVID and look for the RSS link.
StackHealth Time Machine